Gastrointestinal release behaviour of modified-release drug products

Dynamic dissolution testing of mesalazine formulations

Alvaro Goyanes, Grace B. Hatton, Hamid Merchant, Abdul W. Basit

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dynamic conditions of the gastrointestinal tract. Monolithic and multi-particulate mesalazine formulations with pH-dependent and/or independent release mechanisms were evaluated (Asacol® 800, Octasa®, Mezavant® XL, Salofalk®, Pentasa®), and each of the products displayed a distinctive dissolution profile. The dissolution results for Mezavant® XL (Lialda®) (lag time 290 min) demonstrated good correlation with previously reported in vivo disintegration times assessed by gamma-scintigraphy in humans. Octasa® showed a similar lag time to Mezavant® XL. Drug release from Asacol® 800 (Asacol® HD) showed a wide standard deviation, reflecting the great variability in vivo. Salofalk® displayed both delayed release and extended release characteristics. Pentasa® released more than 50% of its drug load in the stomach compartment of the model, which is attributed to the absence of a gastro-resistant coating in this product. The new dissolution method provided a realistic and discriminative in vitro assessment of mesalazine release from different formulations. These results demonstrate that this strategy can be used to predict intestinal release behaviour, and potentially aid the rational design of products developed to target different sites of the gut.
Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalInternational Journal of Pharmaceutics
Volume484
Issue number1-2
Early online date23 Feb 2015
DOIs
Publication statusPublished - Apr 2015

Fingerprint

Mesalamine
Drug Liberation
Bicarbonates
Ulcerative Colitis
Radionuclide Imaging
Gastrointestinal Tract
Stomach
Buffers

Cite this

@article{b49c67a53c9a45848c8c47c89faf787b,
title = "Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations",
abstract = "The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dynamic conditions of the gastrointestinal tract. Monolithic and multi-particulate mesalazine formulations with pH-dependent and/or independent release mechanisms were evaluated (Asacol{\circledR} 800, Octasa{\circledR}, Mezavant{\circledR} XL, Salofalk{\circledR}, Pentasa{\circledR}), and each of the products displayed a distinctive dissolution profile. The dissolution results for Mezavant{\circledR} XL (Lialda{\circledR}) (lag time 290 min) demonstrated good correlation with previously reported in vivo disintegration times assessed by gamma-scintigraphy in humans. Octasa{\circledR} showed a similar lag time to Mezavant{\circledR} XL. Drug release from Asacol{\circledR} 800 (Asacol{\circledR} HD) showed a wide standard deviation, reflecting the great variability in vivo. Salofalk{\circledR} displayed both delayed release and extended release characteristics. Pentasa{\circledR} released more than 50{\%} of its drug load in the stomach compartment of the model, which is attributed to the absence of a gastro-resistant coating in this product. The new dissolution method provided a realistic and discriminative in vitro assessment of mesalazine release from different formulations. These results demonstrate that this strategy can be used to predict intestinal release behaviour, and potentially aid the rational design of products developed to target different sites of the gut.",
author = "Alvaro Goyanes and Hatton, {Grace B.} and Hamid Merchant and Basit, {Abdul W.}",
year = "2015",
month = "4",
doi = "10.1016/j.ijpharm.2015.02.051",
language = "English",
volume = "484",
pages = "103--108",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

Gastrointestinal release behaviour of modified-release drug products : Dynamic dissolution testing of mesalazine formulations. / Goyanes, Alvaro; Hatton, Grace B.; Merchant, Hamid; Basit, Abdul W.

In: International Journal of Pharmaceutics, Vol. 484, No. 1-2, 04.2015, p. 103-108.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gastrointestinal release behaviour of modified-release drug products

T2 - Dynamic dissolution testing of mesalazine formulations

AU - Goyanes, Alvaro

AU - Hatton, Grace B.

AU - Merchant, Hamid

AU - Basit, Abdul W.

PY - 2015/4

Y1 - 2015/4

N2 - The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dynamic conditions of the gastrointestinal tract. Monolithic and multi-particulate mesalazine formulations with pH-dependent and/or independent release mechanisms were evaluated (Asacol® 800, Octasa®, Mezavant® XL, Salofalk®, Pentasa®), and each of the products displayed a distinctive dissolution profile. The dissolution results for Mezavant® XL (Lialda®) (lag time 290 min) demonstrated good correlation with previously reported in vivo disintegration times assessed by gamma-scintigraphy in humans. Octasa® showed a similar lag time to Mezavant® XL. Drug release from Asacol® 800 (Asacol® HD) showed a wide standard deviation, reflecting the great variability in vivo. Salofalk® displayed both delayed release and extended release characteristics. Pentasa® released more than 50% of its drug load in the stomach compartment of the model, which is attributed to the absence of a gastro-resistant coating in this product. The new dissolution method provided a realistic and discriminative in vitro assessment of mesalazine release from different formulations. These results demonstrate that this strategy can be used to predict intestinal release behaviour, and potentially aid the rational design of products developed to target different sites of the gut.

AB - The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dynamic conditions of the gastrointestinal tract. Monolithic and multi-particulate mesalazine formulations with pH-dependent and/or independent release mechanisms were evaluated (Asacol® 800, Octasa®, Mezavant® XL, Salofalk®, Pentasa®), and each of the products displayed a distinctive dissolution profile. The dissolution results for Mezavant® XL (Lialda®) (lag time 290 min) demonstrated good correlation with previously reported in vivo disintegration times assessed by gamma-scintigraphy in humans. Octasa® showed a similar lag time to Mezavant® XL. Drug release from Asacol® 800 (Asacol® HD) showed a wide standard deviation, reflecting the great variability in vivo. Salofalk® displayed both delayed release and extended release characteristics. Pentasa® released more than 50% of its drug load in the stomach compartment of the model, which is attributed to the absence of a gastro-resistant coating in this product. The new dissolution method provided a realistic and discriminative in vitro assessment of mesalazine release from different formulations. These results demonstrate that this strategy can be used to predict intestinal release behaviour, and potentially aid the rational design of products developed to target different sites of the gut.

U2 - 10.1016/j.ijpharm.2015.02.051

DO - 10.1016/j.ijpharm.2015.02.051

M3 - Article

VL - 484

SP - 103

EP - 108

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -